Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway

The activity of the key DNA-damage response (DDR) kinases, ATR and ATM, is largely compromised in chronic lymphocytic leukemia (CLL) cells. While noncycling CLL cells lack ATR protein expression,[1] ATM is commonly targeted for inactivation by genetic abnormalities of the ATM gene.[2] It has been shown that checkpoint pathways, which operate in cycling somatic cells and target Cdk2 kinase activity, are to some extent activated in arrested CLL cells after DNA damage as well;[3] however, the impact of these pathways is questionable, as it could be hampered by predominantly cytoplasmic localization of Cdk2 in CLL cells.[4] Nevertheless, DDR plays a key role in sensitivity of CLL to chemotherapy. Another stress-response kinase, p38 MAP kinase (p38MAPK), was shown to promote CLL cells survival.[5] In multiple cell types, p38MAPK activates different cell cycle checkpoints (mainly through regulation of cyclindependent kinase (Cdk) inhibitors p21Cip1 and p27Kip1), and also ATM/ATR-dependent G2/M checkpoint signaling through MAPKAP kinase-2 activity.[6] While relationship between ATM/p53 and p21Cip1 expression in CLL was studied,[7] the association of ATM kinase activity with the levels of p27Kip1 after DNA damage has not been elucidated in CLL cells.

[1]  P. Mehdipour,et al.  Linking ATM Promoter Methylation to Cell Cycle Protein Expression in Brain Tumor Patients: Cellular Molecular Triangle Correlation in ATM Territory , 2015, Molecular Neurobiology.

[2]  A. Pettitt,et al.  Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC‐wide approach , 2014, British journal of haematology.

[3]  D. Colomer,et al.  High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle , 2014, Oncotarget.

[4]  M. Fujita,et al.  ATM regulates Cdt1 stability during the unperturbed S phase to prevent re-replication , 2013, Cell cycle.

[5]  A. Pettitt,et al.  Assessment of TP 53 functionality in chronic lymphocytic leukaemia by different assays , 2014 .

[6]  Š. Pospíšilová,et al.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin , 2013, Haematologica.

[7]  M. Dyer,et al.  Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gatti,et al.  ATM is down-regulated by N-Myc–regulated microRNA-421 , 2010, Proceedings of the National Academy of Sciences.

[9]  M. Cuadrado,et al.  p27Kip1 stabilization is essential for the maintenance of cell cycle arrest in response to DNA damage. , 2009, Cancer research.

[10]  M. Yaffe,et al.  Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. , 2009, Current opinion in cell biology.

[11]  K. Kuliczkowski,et al.  High intracellular content of cyclin‐dependent kinase inhibitor p27Kip1 in early‐ and intermediate stage B‐cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease , 2009, European journal of haematology.

[12]  F. Davi,et al.  High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia , 2006, Leukemia.

[13]  A. Pettitt,et al.  The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes , 2004, Oncogene.

[14]  J. Decaprio,et al.  Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases , 2003, Leukemia.

[15]  J. Herman,et al.  CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. , 2002, Blood.

[16]  Y Taya,et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. , 1998, Science.